Founded in 1981, Purolite is a leading manufacturer of ion exchange media, polymeric adsorbents, catalysts and advanced polymers. Headquartered in Bala Cynwyd, PA., the company has manufacturing facilities in the USA, China, Romania and the UK, and operates dedicated R&D centers in the USA, China, Romania, Russia and the UK. Purolite has a network of over 40 offices in over 30 countries to provide customers with easy access to the largest technical sales and support network in the industry.
Started in 2012, Purolite Life Sciences supports R&D and production-scale applications in pharmaceuticals, food production, bioprocessing, fine chemical and other markets. Its portfolio includes high-quality resins for enzyme immobilization, adsorption, extraction, and chromatography, and finished products for biocatalysis. For over 25 years, Purolite resins and adsorbents have been used in drug formulations as active pharmaceutical ingredients (APIs) and excipients from its FDA inspected facility. Purolite is the only globally-active company that focuses its R&D investment exclusively on advanced resin technology. In addition to perfecting existing products, Purolite aim to discover new products for new applications, by developing products that address specific challenges that customers face.
Over the past decade we have seen an increase in the resin options available for chromatography. These new resins have different chemical compositions and molecules access them differently. Thus, they provide a more "fit for ... Continued
Combining Ion Exchange and Reverse Phase Chromatography for Highly Efficient and Cost Effective Peptide Purification
Therapeutic peptide purification can be very challenging because of the similarities between peptides and their impurities. There is not a significant difference in retention for the target peptide and a peptide contaminant that has one ... Continued
Increasing upstream titers, the need to increase throughput of existing facilities and the desire to reduce costs are just a few of the drivers forcing paradigm shifts in monoclonal antibody (mAb) downstream processes. These drivers ... Continued
To ensure a safe and continuous supply of life-saving biopharmaceuticals, raw materials for biomanufacturing must be selected carefully and suppliers evaluated with much scrutiny. Several instances of drug shortages as the result of either a ... Continued
The vast majority of chromatography resins designed for large-scale bioprocess chromatography separation are produced using traditional batch emulsification in conventional stirred-tank reactors. In these cases, the size of the beads formed in the reactor is ... Continued
Pre-activated Resins for Ligand Immobilization to facilitate the Creation of Customized Affinity Purification Media
To enable the development of customized affinity purification media, Purolite has recently launched three pre-activated resins for ligand immobilization. The resins, Praesto NHS, Praesto CNBr, and Praesto Epoxy and are well suited for research, diagnostic and academic applications and are available in three particle sizes - 45μm, 65μm and 90μm....Continued
Lowering MAb Clinical Trial Material Manufacturing Costs with Purpose-designed Protein A Chromatography Resins – A Case Study
The use of Protein A affinity chromatography is commonplace in biopharmaceutical manufacturing, with 95% of all commercially available MAbs using Protein A purification. High purity is achieved in one step (around 99%), but it is ... Continued